<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:49:13 -0700</creation_date>
  <update_date>2013-05-27 11:04:07 -0600</update_date>
  <accession>HMDBP00169</accession>
  <secondary_accessions>
    <accession>5401</accession>
    <accession>HMDBP03761</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>MAO-A</synonym>
    <synonym>Monoamine oxidase type A</synonym>
  </synonyms>
  <gene_name>MAOA</gene_name>
  <general_function>Involved in oxidoreductase activity</general_function>
  <specific_function>Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
</specific_function>
  <pathways>
    <pathway>
      <name>Glycine, serine and threonine metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00260</kegg_map_id>
    </pathway>
    <pathway>
      <name>Arginine and proline metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00330</kegg_map_id>
    </pathway>
    <pathway>
      <name>Histidine metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00340</kegg_map_id>
    </pathway>
    <pathway>
      <name>Tyrosine metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00350</kegg_map_id>
    </pathway>
    <pathway>
      <name>Phenylalanine metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00360</kegg_map_id>
    </pathway>
    <pathway>
      <name>Tryptophan metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00380</kegg_map_id>
    </pathway>
    <pathway>
      <name>Drug metabolism - cytochrome P450</name>
      <smpdb_id/>
      <kegg_map_id>map00982</kegg_map_id>
    </pathway>
    <pathway>
      <name>Serotonergic synapse</name>
      <smpdb_id/>
      <kegg_map_id>map04726</kegg_map_id>
    </pathway>
    <pathway>
      <name>Dopaminergic synapse</name>
      <smpdb_id/>
      <kegg_map_id>map04728</kegg_map_id>
    </pathway>
    <pathway>
      <name>Cocaine addiction</name>
      <smpdb_id/>
      <kegg_map_id>map05030</kegg_map_id>
    </pathway>
    <pathway>
      <name>Amphetamine addiction</name>
      <smpdb_id/>
      <kegg_map_id>map05031</kegg_map_id>
    </pathway>
    <pathway>
      <name>Alcoholism</name>
      <smpdb_id/>
      <kegg_map_id>map05034</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00898</accession>
      <name>1-Methylhistamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04181</accession>
      <name>Methylimidazole acetaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02117</accession>
      <name>Oleamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06236</accession>
      <name>Phenylacetaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04073</accession>
      <name>5-Hydroxyindoleacetaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04095</accession>
      <name>5-Methoxytryptamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04369</accession>
      <name>N-Methylserotonin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04076</accession>
      <name>5-Hydroxykynurenamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04077</accession>
      <name>4,6-Dihydroxyquinoline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00259</accession>
      <name>Serotonin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00303</accession>
      <name>Tryptamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01190</accession>
      <name>Indoleacetaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05175</accession>
      <name>Homovanillin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04061</accession>
      <name>3-Methoxy-4-hydroxyphenylglycolaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00022</accession>
      <name>3-Methoxytyramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06242</accession>
      <name>3,4-Dihydroxymandelaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03791</accession>
      <name>3,4-Dihydroxyphenylacetaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00073</accession>
      <name>Dopamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00068</accession>
      <name>Epinephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04063</accession>
      <name>Metanephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00216</accession>
      <name>Norepinephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00819</accession>
      <name>Normetanephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00306</accession>
      <name>Tyramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02064</accession>
      <name>N-Acetylputrescine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04226</accession>
      <name>N4-Acetylaminobutanal</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01248</accession>
      <name>FAD</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02182</accession>
      <name>Phenylephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01848</accession>
      <name>Imipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00234</accession>
      <name>Testosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01943</accession>
      <name>Pseudoephedrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01942</accession>
      <name>Phenylpropanolamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05037</accession>
      <name>Sumatriptan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00051</accession>
      <name>Ammonia</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00087</accession>
      <name>Dimethylamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00164</accession>
      <name>Methylamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01167</accession>
      <name>Pyruvaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01377</accession>
      <name>Oxygen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02017</accession>
      <name>1-Phenylethylamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02134</accession>
      <name>Aminoacetone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03125</accession>
      <name>Hydrogen peroxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05038</accession>
      <name>Citalopram</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00244</accession>
      <name>Riboflavin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01934</accession>
      <name>L(-)-Nicotine pestanal</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14337</accession>
      <name>Phentermine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14460</accession>
      <name>Zolmitriptan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14739</accession>
      <name>Linezolid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14752</accession>
      <name>Furazolidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14890</accession>
      <name>Tranylcypromine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14918</accession>
      <name>Phenelzine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14943</accession>
      <name>Minaprine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15045</accession>
      <name>Zonisamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15054</accession>
      <name>Almotriptan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15087</accession>
      <name>Naratriptan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15088</accession>
      <name>Rizatriptan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15171</accession>
      <name>Selegiline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15302</accession>
      <name>Moclobemide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15377</accession>
      <name>Isocarboxazid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15517</accession>
      <name>Methamphetamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15563</accession>
      <name>Pargyline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15694</accession>
      <name>Nandrolone decanoate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03767</accession>
      <name>4-Hydroxyphenylacetaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12275</accession>
      <name>Phenylethylamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB60281</accession>
      <name>3-Hydroxykynurenamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB60289</accession>
      <name>Quinoline-4,8-diol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB60462</accession>
      <name>Citalopram aldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14021</accession>
      <name>N-Desmethylcitalopram</name>
    </metabolite>
    <metabolite>
      <accession>HMDB60472</accession>
      <name>Didemethylcitalopram</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>oxidation reduction</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>integral to membrane</description>
      <go_id>GO:0016021</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>mitochondrial outer membrane</description>
      <go_id>GO:0005741</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>flavin adenine dinucleotide binding</description>
      <go_id>GO:0050660</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>primary amine oxidase activity</description>
      <go_id>GO:0008131</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>serotonin binding</description>
      <go_id>GO:0051378</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>behavior</description>
      <go_id>GO:0007610</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cellular biogenic amine metabolic process</description>
      <go_id>GO:0006576</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>dopamine catabolic process</description>
      <go_id>GO:0042420</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>neurotransmitter biosynthetic process</description>
      <go_id>GO:0042136</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>neurotransmitter catabolic process</description>
      <go_id>GO:0042135</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>neurotransmitter secretion</description>
      <go_id>GO:0007269</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>phenylethylamine metabolic process</description>
      <go_id>GO:0042443</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>serotonin metabolic process</description>
      <go_id>GO:0042428</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>small molecule metabolic process</description>
      <go_id>GO:0044281</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>xenobiotic metabolic process</description>
      <go_id>GO:0006805</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Mitochondrion outer membrane</subcellular_location>
    <subcellular_location>Single-pass type IV membrane protein</subcellular_location>
    <subcellular_location>Cytoplasmic side</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>X</chromosome_location>
    <locus>Xp11.3</locus>
    <gene_sequence>&gt;1584 bp
ATGGAGAATCAAGAGAAGGCGAGTATCGCGGGCCACATGTTCGACGTAGTCGTGATCGGA
GGTGGCATTTCAGGACTATCTGCTGCCAAACTCTTGACTGAATATGGCGTTAGTGTTTTG
GTTTTAGAAGCTCGGGACAGGGTTGGAGGAAGAACATATACTATAAGGAATGAGCATGTT
GATTACGTAGATGTTGGTGGAGCTTATGTGGGACCAACCCAAAACAGAATCTTACGCTTG
TCTAAGGAGCTGGGCATAGAGACTTACAAAGTGAATGTCAGTGAGCGTCTCGTTCAATAT
GTCAAGGGGAAAACATATCCATTTCGGGGCGCCTTTCCACCAGTATGGAATCCCATTGCA
TATTTGGATTACAATAATCTGTGGAGGACAATAGATAACATGGGGAAGGAGATTCCAACT
GATGCACCCTGGGAGGCTCAACATGCTGACAAATGGGACAAAATGACCATGAAAGAGCTC
ATTGACAAAATCTGCTGGACAAAGACTGCTAGGCGGTTTGCTTATCTTTTTGTGAATATC
AATGTGACCTCTGAGCCTCACGAAGTGTCTGCCCTGTGGTTCTTGTGGTATGTGAAGCAG
TGCGGGGGCACCACTCGGATATTCTCTGTCACCAATGGTGGCCAGGAACGGAAGTTTGTA
GGTGGATCTGGTCAAGTGAGCGAACGGATAATGGACCTCCTCGGAGACCAAGTGAAGCTG
AACCATCCTGTCACTCACGTTGACCAGTCAAGTGACAACATCATCATAGAGACGCTGAAC
CATGAACATTATGAGTGCAAATACGTAATTAATGCGATCCCTCCGACCTTGACTGCCAAG
ATTCACTTCAGACCAGAGCTTCCAGCAGAGAGAAACCAGTTAATTCAGCGTCTTCCAATG
GGAGCTGTCATTAAGTGCATGATGTATTACAAGGAGGCCTTCTGGAAGAAGAAGGATTAC
TGTGGCTGCATGATCATTGAAGATGAAGATGCTCCAATTTCAATAACCTTGGATGACACC
AAGCCAGATGGGTCACTGCCTGCCATCATGGGCTTCATTCTTGCCCGGAAAGCTGATCGA
CTTGCTAAGCTACATAAGGAAATAAGGAAGAAGAAAATCTGTGAGCTCTATGCCAAAGTG
CTGGGATCCCAAGAAGCTTTACATCCAGTGCATTATGAAGAGAAGAACTGGTGTGAGGAG
CAGTACTCTGGGGGCTGCTACACGGCCTACTTCCCTCCTGGGATCATGACTCAATATGGA
AGGGTGATTCGTCAACCCGTGGGCAGGATTTTCTTTGCGGGCACAGAGACTGCCACAAAG
TGGAGCGGCTACATGGAAGGGGCAGTTGAGGCTGGAGAACGAGCAGCTAGGGAGGTCTTA
AATGGTCTCGGGAAGGTGACCGAGAAAGACATCTGGGTACAAGAACCTGAATCAAAGGAC
GTTCCAGCGGTAGAAATCACCCACACCTTCTGGGAAAGGAACCTGCCCTCTGTTTCTGGC
CTGCTGAAGATCATTGGATTTTCCACATCAGTAACTGCCCTGGGGTTTGTGCTGTACAAA
TACAAGCTCCTGCCACGGTCTTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>527</residue_number>
    <molecular_weight>59681.27</molecular_weight>
    <theoretical_pi>7.862</theoretical_pi>
    <pfams>
      <pfam>
        <name>Amino_oxidase</name>
        <pfam_id>PF01593</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Amine oxidase [flavin-containing] A
MENQEKASIAGHMFDVVVIGGGISGLSAAKLLTEYGVSVLVLEARDRVGGRTYTIRNEHV
DYVDVGGAYVGPTQNRILRLSKELGIETYKVNVSERLVQYVKGKTYPFRGAFPPVWNPIA
YLDYNNLWRTIDNMGKEIPTDAPWEAQHADKWDKMTMKELIDKICWTKTARRFAYLFVNI
NVTSEPHEVSALWFLWYVKQCGGTTRIFSVTNGGQERKFVGGSGQVSERIMDLLGDQVKL
NHPVTHVDQSSDNIIIETLNHEHYECKYVINAIPPTLTAKIHFRPELPAERNQLIQRLPM
GAVIKCMMYYKEAFWKKKDYCGCMIIEDEDAPISITLDDTKPDGSLPAIMGFILARKADR
LAKLHKEIRKKKICELYAKVLGSQEALHPVHYEEKNWCEEQYSGGCYTAYFPPGIMTQYG
RVIRQPVGRIFFAGTETATKWSGYMEGAVEAGERAAREVLNGLGKVTEKDIWVQEPESKD
VPAVEITHTFWERNLPSVSGLLKIIGFSTSVTALGFVLYKYKLLPRS</protein_sequence>
  </protein_properties>
  <genbank_protein_id>187355</genbank_protein_id>
  <uniprot_id>P21397</uniprot_id>
  <uniprot_name>AOFA_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1H8Q</pdb_id>
    <pdb_id>2BXR</pdb_id>
    <pdb_id>2BXS</pdb_id>
    <pdb_id>2Z5X</pdb_id>
    <pdb_id>2Z5Y</pdb_id>
  </pdb_ids>
  <genbank_gene_id>M69226</genbank_gene_id>
  <genecard_id>MAOA</genecard_id>
  <geneatlas_id>MAOA</geneatlas_id>
  <hgnc_id>HGNC:6833</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Hsu YP, Weyler W, Chen S, Sims KB, Rinehart WB, Utterback MC, Powell JF, Breakefield XO: Structural features of human monoamine oxidase A elucidated from cDNA and peptide sequences. J Neurochem. 1988 Oct;51(4):1321-4.</reference_text>
      <pubmed_id>3418353</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bach AW, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC: cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4934-8.</reference_text>
      <pubmed_id>3387449</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chen ZY, Hotamisligil GS, Huang JK, Wen L, Ezzeddine D, Aydin-Muderrisoglu N, Powell JF, Huang RH, Breakefield XO, Craig I, et al.: Structure of the human gene for monoamine oxidase type A.  Nucleic Acids Res. 1991 Aug 25;19(16):4537-41.</reference_text>
      <pubmed_id>1886775</pubmed_id>
    </reference>
    <reference>
      <reference_text>Grimsby J, Chen K, Wang LJ, Lan NC, Shih JC: Human monoamine oxidase A and B genes exhibit identical exon-intron organization. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3637-41.</reference_text>
      <pubmed_id>2023912</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhu QS, Grimsby J, Chen K, Shih JC: Promoter organization and activity of human monoamine oxidase (MAO) A and B genes. J Neurosci. 1992 Nov;12(11):4437-46.</reference_text>
      <pubmed_id>1432104</pubmed_id>
    </reference>
    <reference>
      <reference_text>Denney RM: The promoter of the human monoamine oxidase A gene.  Prog Brain Res. 1995;106:57-66.</reference_text>
      <pubmed_id>8584674</pubmed_id>
    </reference>
    <reference>
      <reference_text>Denney RM, Sharma A, Dave SK, Waguespack A: A new look at the promoter of the human monoamine oxidase A gene: mapping transcription initiation sites and capacity to drive luciferase expression. J Neurochem. 1994 Sep;63(3):843-56.</reference_text>
      <pubmed_id>7519662</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chen SA, Weyler W: Partial amino acid sequence analysis of human placenta monoamine oxidase A and bovine liver monoamine oxidase B. Biochem Biophys Res Commun. 1988 Oct 14;156(1):445-50.</reference_text>
      <pubmed_id>3178846</pubmed_id>
    </reference>
    <reference>
      <reference_text>Weyler W: Monoamine oxidase A from human placenta and monoamine oxidase B from bovine liver both have one FAD per subunit. Biochem J. 1989 Jun 15;260(3):725-9.</reference_text>
      <pubmed_id>2764901</pubmed_id>
    </reference>
    <reference>
      <reference_text>Li M, Hubalek F, Newton-Vinson P, Edmondson DE: High-level expression of human liver monoamine oxidase A in Pichia pastoris: comparison with the enzyme expressed in Saccharomyces cerevisiae. Protein Expr Purif. 2002 Feb;24(1):152-62.</reference_text>
      <pubmed_id>11812236</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wu HF, Chen K, Shih JC: Site-directed mutagenesis of monoamine oxidase A and B: role of cysteines.  Mol Pharmacol. 1993 Jun;43(6):888-93.</reference_text>
      <pubmed_id>8316221</pubmed_id>
    </reference>
    <reference>
      <reference_text>De Colibus L, Li M, Binda C, Lustig A, Edmondson DE, Mattevi A: Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12684-9. Epub 2005 Aug 29.</reference_text>
      <pubmed_id>16129825</pubmed_id>
    </reference>
    <reference>
      <reference_text>Brunner HG, Nelen M, Breakefield XO, Ropers HH, van Oost BA: Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science. 1993 Oct 22;262(5133):578-80.</reference_text>
      <pubmed_id>8211186</pubmed_id>
    </reference>
    <reference>
      <reference_text>Son SY, Ma J, Kondou Y, Yoshimura M, Yamashita E, Tsukihara T: Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5739-44. Epub 2008 Apr 7.</reference_text>
      <pubmed_id>18391214</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers.  Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7.</reference_text>
      <pubmed_id>16959974</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Dopamine</name>
        <accession>HMDB00073</accession>
      </metabolite>
      <reference>
        <reference_text>Bortolato M, Chen K, Shih JC: Monoamine oxidase inactivation: from pathophysiology to therapeutics.  Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1527-33. Epub 2008 Jul 4.</reference_text>
        <pubmed_id>18652859</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dopamine</name>
        <accession>HMDB00073</accession>
      </metabolite>
      <reference>
        <reference_text>Kaludercic N, Carpi A, Menabo R, Di Lisa F, Paolocci N: Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim Biophys Acta. 2011 Jul;1813(7):1323-32. Epub 2010 Sep 24.</reference_text>
        <pubmed_id>20869994</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dopamine</name>
        <accession>HMDB00073</accession>
      </metabolite>
      <reference>
        <reference_text>Volavka J, Bilder R, Nolan K: Catecholamines and aggression: the role of COMT and MAO polymorphisms.  Ann N Y Acad Sci. 2004 Dec;1036:393-8.</reference_text>
        <pubmed_id>15817751</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Testosterone</name>
        <accession>HMDB00234</accession>
      </metabolite>
      <reference>
        <reference_text>Sjoberg RL, Ducci F, Barr CS, Newman TK, Dell'osso L, Virkkunen M, Goldman D: A non-additive interaction of a functional MAO-A VNTR and testosterone predicts antisocial behavior. Neuropsychopharmacology. 2008 Jan;33(2):425-30. Epub 2007 Apr 11.</reference_text>
        <pubmed_id>17429405</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Testosterone</name>
        <accession>HMDB00234</accession>
      </metabolite>
      <reference>
        <reference_text>Hoff KM: Interaction of testosterone with monoamineoxidase in mouse brain maturation.  Gen Pharmacol. 1977;8(1):55-7.</reference_text>
        <pubmed_id>590724</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Riboflavin</name>
        <accession>HMDB00244</accession>
      </metabolite>
      <reference>
        <reference_text>Strolin Benedetti M, Tipton KF, Whomsley R: Amine oxidases and monooxygenases in the in vivo metabolism of xenobiotic amines in humans: has the involvement of amine oxidases been neglected? Fundam Clin Pharmacol. 2007 Oct;21(5):467-80.</reference_text>
        <pubmed_id>17868200</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L(-)-Nicotine pestanal</name>
        <accession>HMDB01934</accession>
      </metabolite>
      <reference>
        <reference_text>Lewis AJ, Truman P, Hosking MR, Miller JH: Monoamine oxidase inhibitory activity in tobacco smoke varies with tobacco type.  Tob Control. 2012 Jan;21(1):39-43. Epub 2011 Jun 2.</reference_text>
        <pubmed_id>21636610</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L(-)-Nicotine pestanal</name>
        <accession>HMDB01934</accession>
      </metabolite>
      <reference>
        <reference_text>Leroy C, Bragulat V, Berlin I, Gregoire MC, Bottlaender M, Roumenov D, Dolle F, Bourgeois S, Penttila J, Artiges E, Martinot JL, Trichard C: Cerebral monoamine oxidase A inhibition in tobacco smokers confirmed with PET and [11C]befloxatone. J Clin Psychopharmacol. 2009 Feb;29(1):86-8.</reference_text>
        <pubmed_id>19142115</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Rothman RB: Is phentermine an inhibitor of monoamine oxidase? A critical appraisal.  Synapse. 1999 May;32(2):141-5.</reference_text>
        <pubmed_id>10231134</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21.</reference_text>
        <pubmed_id>10799660</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Kilpatrick IC, Traut M, Heal DJ: Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release. Int J Obes Relat Metab Disord. 2001 Oct;25(10):1454-8.</reference_text>
        <pubmed_id>11673765</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentermine</name>
        <accession>HMDB14337</accession>
      </metabolite>
      <reference>
        <reference_text>Nandigama RK, Newton-Vinson P, Edmondson DE: Phentermine inhibition of recombinant human liver monoamine oxidases A and B.  Biochem Pharmacol. 2002 Mar 1;63(5):865-9.</reference_text>
        <pubmed_id>11911838</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zolmitriptan</name>
        <accession>HMDB14460</accession>
      </metabolite>
      <reference>
        <reference_text>Rolan P: Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia. 1997 Oct;17 Suppl 18:21-7.</reference_text>
        <pubmed_id>9399014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zolmitriptan</name>
        <accession>HMDB14460</accession>
      </metabolite>
      <reference>
        <reference_text>Wild MJ, McKillop D, Butters CJ: Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan. Xenobiotica. 1999 Aug;29(8):847-57.</reference_text>
        <pubmed_id>10553725</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Linezolid</name>
        <accession>HMDB14739</accession>
      </metabolite>
      <reference>
        <reference_text>Stevens DL, Dotter B, Madaras-Kelly K: A review of linezolid: the first oxazolidinone antibiotic.  Expert Rev Anti Infect Ther. 2004 Feb;2(1):51-9.</reference_text>
        <pubmed_id>15482171</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Linezolid</name>
        <accession>HMDB14739</accession>
      </metabolite>
      <reference>
        <reference_text>Taylor JJ, Wilson JW, Estes LL: Linezolid and serotonergic drug interactions: a retrospective survey.  Clin Infect Dis. 2006 Jul 15;43(2):180-7. Epub 2006 Jun 9.</reference_text>
        <pubmed_id>16779744</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Furazolidone</name>
        <accession>HMDB14752</accession>
      </metabolite>
      <reference>
        <reference_text>Timperio AM, Kuiper HA, Zolla L: Identification of a furazolidone metabolite responsible for the inhibition of amino oxidases. Xenobiotica. 2003 Feb;33(2):153-67.</reference_text>
        <pubmed_id>12623758</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Furazolidone</name>
        <accession>HMDB14752</accession>
      </metabolite>
      <reference>
        <reference_text>Ali BH: Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research. Vet Res Commun. 1999 Oct;23(6):343-60.</reference_text>
        <pubmed_id>10543364</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Furazolidone</name>
        <accession>HMDB14752</accession>
      </metabolite>
      <reference>
        <reference_text>Hoogenboom LA, Tomassini O, Oorsprong MB, Kuiper HA: Use of pig hepatocytes to study the inhibition of monoamine oxidase by furazolidone. Food Chem Toxicol. 1991 Mar;29(3):185-91.</reference_text>
        <pubmed_id>2032659</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly.  Drugs Aging. 1998 Nov;13(5):341-55.</reference_text>
        <pubmed_id>9829163</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Shioda K, Nisijima K, Yoshino T, Kato S: Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome.  Neurosci Lett. 2010 Oct 4;482(3):216-9. Epub 2010 Jul 23.</reference_text>
        <pubmed_id>20655983</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Gatch MB, Taylor CM, Flores E, Selvig M, Forster MJ: Effects of monoamine oxidase inhibitors on cocaine discrimination in rats.  Behav Pharmacol. 2006 Mar;17(2):151-9.</reference_text>
        <pubmed_id>16495723</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Lang W, Masucci JA, Caldwell GW, Hageman W, Hall J, Jones WJ, Rafferty BM: Liquid chromatographic and tandem mass spectrometric assay for evaluation of in vivo inhibition of rat brain monoamine oxidases (MAO) A and B following a single dose of MAO inhibitors: application of biomarkers in drug discovery. Anal Biochem. 2004 Oct 1;333(1):79-87.</reference_text>
        <pubmed_id>15351283</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Shioda K, Nisijima K, Yoshino T, Kato S: Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):633-40.</reference_text>
        <pubmed_id>15276688</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76.</reference_text>
        <pubmed_id>15049511</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3.</reference_text>
        <pubmed_id>14574774</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Cohen C, Curet O, Perrault G, Sanger DJ: Reduction of oral ethanol self-administration in rats by monoamine oxidase inhibitors. Pharmacol Biochem Behav. 1999 Nov;64(3):535-9.</reference_text>
        <pubmed_id>10548268</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Wiest SA, Steinberg MI: 3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine. Naunyn Schmiedebergs Arch Pharmacol. 1999 Aug;360(2):209-16.</reference_text>
        <pubmed_id>10494892</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Loscher W, Lehmann H, Teschendorf HJ, Traut M, Gross G: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther. 1999 Mar;288(3):984-92.</reference_text>
        <pubmed_id>10027835</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Todd KG, Baker GB: GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord. 1995 Dec 13;35(3):125-9.</reference_text>
        <pubmed_id>8749840</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Finberg JP, Youdim MB: Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology. 2002 Dec;43(7):1110-8.</reference_text>
        <pubmed_id>12504917</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Chiche F, Le Guillou M, Chetrite G, Lasnier F, Dugail I, Carpene C, Moldes M, Feve B: Antidepressant phenelzine alters differentiation of cultured human and mouse preadipocytes. Mol Pharmacol. 2009 May;75(5):1052-61. Epub 2009 Feb 6.</reference_text>
        <pubmed_id>19201819</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Chenu F, El Mansari M, Blier P: Long-term administration of monoamine oxidase inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area. Int J Neuropsychopharmacol. 2009 May;12(4):475-85. Epub 2008 Aug 13.</reference_text>
        <pubmed_id>18700056</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Wooters TE, Bardo MT: The monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of nicotine in rats. Behav Pharmacol. 2007 Nov;18(7):601-8.</reference_text>
        <pubmed_id>17912044</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly.  Drugs Aging. 1998 Nov;13(5):341-55.</reference_text>
        <pubmed_id>9829163</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression]. Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3.</reference_text>
        <pubmed_id>14574774</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Pickar D, Murphy DL, Cohen RM, Campbell IC, Lipper S: Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients. Arch Gen Psychiatry. 1982 May;39(5):535-40.</reference_text>
        <pubmed_id>7092487</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>MacKenzie EM, Grant SL, Baker GB, Wood PL: Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition. Neurochem Res. 2008 Mar;33(3):430-6. Epub 2007 Aug 31.</reference_text>
        <pubmed_id>17768678</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH: The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf. 2006 Jan;5(1):157-68.</reference_text>
        <pubmed_id>16370964</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Minaprine</name>
        <accession>HMDB14943</accession>
      </metabolite>
      <reference>
        <reference_text>Kan JP, Mouget-Goniot C, Worms P, Biziere K: Effect of the antidepressant minaprine on both forms of monoamine oxidase in the rat. Biochem Pharmacol. 1986 Mar 15;35(6):973-8.</reference_text>
        <pubmed_id>3954800</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, Fukushima Y: Effects of zonisamide on dopaminergic system.  Epilepsy Res. 1995 Nov;22(3):193-205.</reference_text>
        <pubmed_id>8991786</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Murata M: Zonisamide: a new drug for Parkinson's disease.  Drugs Today (Barc). 2010 Apr;46(4):251-8.</reference_text>
        <pubmed_id>20502722</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Almotriptan</name>
        <accession>HMDB15054</accession>
      </metabolite>
      <reference>
        <reference_text>McEnroe JD, Fleishaker JC: Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.</reference_text>
        <pubmed_id>15762767</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Almotriptan</name>
        <accession>HMDB15054</accession>
      </metabolite>
      <reference>
        <reference_text>Gras J, Llenas J, Jansat JM, Jauregui J, Cabarrocas X, Palacios JM: Almotriptan, a new anti-migraine agent: a review.  CNS Drug Rev. 2002 Fall;8(3):217-34.</reference_text>
        <pubmed_id>12353056</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Almotriptan</name>
        <accession>HMDB15054</accession>
      </metabolite>
      <reference>
        <reference_text>Salva M, Jansat JM, Martinez-Tobed A, Palacios JM: Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.</reference_text>
        <pubmed_id>12642466</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naratriptan</name>
        <accession>HMDB15087</accession>
      </metabolite>
      <reference>
        <reference_text>Millson DS, Tepper SJ, Rapoport AM: Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. Expert Opin Pharmacother. 2000 Mar;1(3):391-404.</reference_text>
        <pubmed_id>11249525</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rizatriptan</name>
        <accession>HMDB15088</accession>
      </metabolite>
      <reference>
        <reference_text>Iwasa T, Sano H, Sugiura A, Uchiyama N, Hara K, Okochi H, Nakagawa K, Yasumori T, Ishizaki T: An in vitro interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug. Br J Clin Pharmacol. 2003 Nov;56(5):537-44.</reference_text>
        <pubmed_id>14651728</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rizatriptan</name>
        <accession>HMDB15088</accession>
      </metabolite>
      <reference>
        <reference_text>Van Haarst AD, Van Gerven JM, Cohen AF, De Smet M, Sterrett A, Birk KL, Fisher AL, De Puy ME, Goldberg MR, Musson DG: The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers. Br J Clin Pharmacol. 1999 Aug;48(2):190-6.</reference_text>
        <pubmed_id>10417495</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>Patkar AA, Pae CU, Masand PS: Transdermal selegiline: the new generation of monoamine oxidase inhibitors.  CNS Spectr. 2006 May;11(5):363-75.</reference_text>
        <pubmed_id>16641841</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C: Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22.</reference_text>
        <pubmed_id>17715422</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder.  Neuropsychiatr Dis Treat. 2007;3(5):527-37.</reference_text>
        <pubmed_id>19300583</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>Baker GB, Sowa B, Todd KG: Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007 Sep;32(5):313-5.</reference_text>
        <pubmed_id>17823646</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Moclobemide</name>
        <accession>HMDB15302</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Moclobemide</name>
        <accession>HMDB15302</accession>
      </metabolite>
      <reference>
        <reference_text>Berlin I, Zimmer R, Thiede HM, Payan C, Hergueta T, Robin L, Puech AJ: Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br J Clin Pharmacol. 1990 Dec;30(6):805-16.</reference_text>
        <pubmed_id>1705137</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Moclobemide</name>
        <accession>HMDB15302</accession>
      </metabolite>
      <reference>
        <reference_text>Fulton B, Benfield P: Moclobemide. An update of its pharmacological properties and therapeutic use.  Drugs. 1996 Sep;52(3):450-74.</reference_text>
        <pubmed_id>8875133</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isocarboxazid</name>
        <accession>HMDB15377</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isocarboxazid</name>
        <accession>HMDB15377</accession>
      </metabolite>
      <reference>
        <reference_text>Thase ME, Trivedi MH, Rush AJ: MAOIs in the contemporary treatment of depression.  Neuropsychopharmacology. 1995 May;12(3):185-219.</reference_text>
        <pubmed_id>7612154</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isocarboxazid</name>
        <accession>HMDB15377</accession>
      </metabolite>
      <reference>
        <reference_text>Kettler R, Da Prada M, Burkard WP: Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiatr Scand Suppl. 1990;360:101-2.</reference_text>
        <pubmed_id>2248058</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Sulzer D, Sonders MS, Poulsen NW, Galli A: Mechanisms of neurotransmitter release by amphetamines: a review.  Prog Neurobiol. 2005 Apr;75(6):406-33.</reference_text>
        <pubmed_id>15955613</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methamphetamine</name>
        <accession>HMDB15517</accession>
      </metabolite>
      <reference>
        <reference_text>Ulus IH, Maher TJ, Wurtman RJ: Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. Biochem Pharmacol. 2000 Jun 15;59(12):1611-21.</reference_text>
        <pubmed_id>10799660</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Patkar AA, Pae CU, Masand PS: Transdermal selegiline: the new generation of monoamine oxidase inhibitors.  CNS Spectr. 2006 May;11(5):363-75.</reference_text>
        <pubmed_id>16641841</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C: Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22.</reference_text>
        <pubmed_id>17715422</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder.  Neuropsychiatr Dis Treat. 2007;3(5):527-37.</reference_text>
        <pubmed_id>19300583</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Baker GB, Sowa B, Todd KG: Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007 Sep;32(5):313-5.</reference_text>
        <pubmed_id>17823646</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Murphy DL, Karoum F, Pickar D, Cohen RM, Lipper S, Mellow AM, Tariot PN, Sunderland T: Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). J Neural Transm Suppl. 1998;52:39-48.</reference_text>
        <pubmed_id>9564606</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pargyline</name>
        <accession>HMDB15563</accession>
      </metabolite>
      <reference>
        <reference_text>Fuentes JA, Ordaz A, Neff NH: Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats. Eur J Pharmacol. 1979 Jul 15;57(1):21-7.</reference_text>
        <pubmed_id>477738</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nandrolone decanoate</name>
        <accession>HMDB15694</accession>
      </metabolite>
      <reference>
        <reference_text>Birgner C, Kindlundh-Hogberg AM, Oreland L, Alsio J, Lindblom J, Schioth HB, Bergstrom L: Reduced activity of monoamine oxidase in the rat brain following repeated nandrolone decanoate administration. Brain Res. 2008 Jul 11;1219:103-10. Epub 2008 May 17.</reference_text>
        <pubmed_id>18539264</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
